Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $63.00 by Analysts at Oppenheimer

Keros Therapeutics (NASDAQ:KROS – Free Report) had its price target trimmed by Oppenheimer from $102.00 to $63.00 in a report released on Monday, MarketBeat Ratings reports. The firm currently has an outperform rating on the stock. A number of other analysts have also recently weighed in on KROS. BTIG Research cut shares of Keros Therapeutics […]

Leave a Reply

Your email address will not be published.

Previous post a.k.a. Brands (NYSE:AKA) Earns Buy Rating from Analysts at Lake Street Capital
Next post Today in History: December 19, Bill Clinton is impeached